Angina Pectoris Drugs Market by Type (Prinzmetal Angina, Stable Angina, Unstable Angina), Drugs (Anti-Ischemic Agents, Antihypertensive Agents, Antiplatelet Agents), Route of Administration, Distribution Channel, End-Users - Global Forecast 2024-2030
The Angina Pectoris Drugs Market size was estimated at USD 1.14 billion in 2023 and expected to reach USD 1.20 billion in 2024, at a CAGR 5.39% to reach USD 1.65 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Angina Pectoris Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Angina Pectoris Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Angina Pectoris Drugs Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Limited, Alkem Laboratories Ltd., Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Centurion Remedies Private Limited, Dr. Reddy's Laboratories, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline PLC, Intas Pharmaceuticals Ltd., Ipca Laboratories Ltd., Lupin Ltd., Macleods Pharmaceuticals Pvt Ltd., Mankind Pharma, Merck & Co. Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi-Aventis Groupe S.A., Sumitomo Corporation, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Torrent Pharmaceuticals Ltd..
Market Segmentation & Coverage
This research report categorizes the Angina Pectoris Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
Type
Prinzmetal Angina
Stable Angina
Unstable Angina
Drugs
Anti-Ischemic Agents
Antihypertensive Agents
Antiplatelet Agents
Beta-Adrenergic Blocking Agents
Calcium Channel Blockers
Nitrates
Statins
Route of Administration
Oral
Parenteral
Transdermal
Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
End-Users
Homecare
Hospitals
Specialty Clinics
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom The report offers valuable insights on the following aspects:
Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
What is the market size and forecast of the Angina Pectoris Drugs Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Angina Pectoris Drugs Market?
What are the technology trends and regulatory frameworks in the Angina Pectoris Drugs Market?
What is the market share of the leading vendors in the Angina Pectoris Drugs Market?
Which modes and strategic moves are suitable for entering the Angina Pectoris Drugs Market?
Note: PDF & Excel + Online Access - 1 Year
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Angina Pectoris Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing burden of lifestyle diseases couple with rise in cases of heart related disorders
5.1.1.2. Augmentation of novel drug delivery systems
5.1.1.3. Government suppport in strengthening the prevention and control of cardiovascular disease
5.1.2. Restraints
5.1.2.1. Concerns regarding side effects associated with certain drug classes
5.1.3. Opportunities
5.1.3.1. Technological advancements towards personalized cardiovascular medicine
5.1.3.2. Proliferation in the number of drug approvals and clinical research
5.1.4. Challenges
5.1.4.1. Dearth of skilled and experienced professionals
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Angina Pectoris Drugs Market, by Type
6.1. Introduction
6.2. Prinzmetal Angina
6.3. Stable Angina
6.4. Unstable Angina
7. Angina Pectoris Drugs Market, by Drugs
7.1. Introduction
7.2. Anti-Ischemic Agents
7.3. Antihypertensive Agents
7.4. Antiplatelet Agents
7.5. Beta-Adrenergic Blocking Agents
7.6. Calcium Channel Blockers
7.7. Nitrates
7.8. Statins
8. Angina Pectoris Drugs Market, by Route of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
8.4. Transdermal
9. Angina Pectoris Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Angina Pectoris Drugs Market, by End-Users
10.1. Introduction
10.2. Homecare
10.3. Hospitals
10.4. Specialty Clinics
11. Americas Angina Pectoris Drugs Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Angina Pectoris Drugs Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Angina Pectoris Drugs Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. Alembic Pharmaceuticals Limited
15.1.2. Alkem Laboratories Ltd.
15.1.3. Astellas Pharma Inc.
15.1.4. AstraZeneca PLC
15.1.5. Bausch Health Companies Inc.
15.1.6. Bayer AG
15.1.7. Centurion Remedies Private Limited
15.1.8. Dr. Reddy's Laboratories
15.1.9. Eli Lilly and Company
15.1.10. Gilead Sciences, Inc.
15.1.11. GlaxoSmithKline PLC
15.1.12. Intas Pharmaceuticals Ltd.
15.1.13. Ipca Laboratories Ltd.
15.1.14. Lupin Ltd.
15.1.15. Macleods Pharmaceuticals Pvt Ltd.
15.1.16. Mankind Pharma
15.1.17. Merck & Co. Inc.
15.1.18. Novartis AG
15.1.19. Otsuka Pharmaceutical Co., Ltd.
15.1.20. Pfizer Inc.
15.1.21. Sanofi-Aventis Groupe S.A.
15.1.22. Sumitomo Corporation
15.1.23. Sun Pharmaceutical Industries Ltd.
15.1.24. Teva Pharmaceutical Industries Ltd.
15.1.25. Torrent Pharmaceuticals Ltd.
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
FIGURE 1. ANGINA PECTORIS DRUGS MARKET RESEARCH PROCESS
FIGURE 2. ANGINA PECTORIS DRUGS MARKET SIZE, 2023 VS 2030